Xavier Poiré

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

Nicolaus Kröger, Simona Iacobelli, Georg‐Nikolaus Franke et al. · Journal of Clinical Oncology · 2017 · 238 citations · Full text

Cell Therapy, Immunology, Myeloid Neoplasia +16

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

Johan Maertens, Catherine Cordonnier, Péter Jaksch et al. · New England Journal of Medicine · 2019 · 175 citations · Full text

Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen—A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Arnon Nagler, Vanderson Rocha, Myriam Labopin et al. · Journal of Clinical Oncology · 2013 · 171 citations · Full text

Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial

Nitin Jain, Emily Curran, Neil M. Iyengar et al. · Clinical Cancer Research · 2013 · 111 citations · Full text

Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Donal P. McLornan, Richard Szydlo, Linda Köster et al. · Biology of Blood and Marrow Transplantation · 2019 · 94 citations · Full text